Compare OZK & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZK | APGE |
|---|---|---|
| Founded | 1903 | 2022 |
| Country | United States | United States |
| Employees | 3280 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | OZK | APGE |
|---|---|---|
| Price | $51.07 | $132.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $55.00 | ★ $109.67 |
| AVG Volume (30 Days) | 1.0M | ★ 4.0M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.37 | $34.34 |
| 52 Week High | $53.66 | $133.16 |
| Indicator | OZK | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 81.42 |
| Support Level | $50.34 | $75.41 |
| Resistance Level | $52.65 | N/A |
| Average True Range (ATR) | 1.13 | 4.21 |
| MACD | -0.02 | 5.57 |
| Stochastic Oscillator | 58.43 | 99.15 |
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides banking services, including checking, savings, money market, time deposits, and individual retirement accounts, as well as loan services, such as real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services, it also provides trust and wealth management, financial planning, online banking, and other related services.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.